Study: Most Blood Cancer Patients Could Benefit From Additional Dose of COVID-19 Vaccine
September 30th 2021Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.
Read More
The Changing Landscape of Relapsed/Refractory Chronic Lymphocytic Leukemia Treatment
September 30th 2021Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.
Read More
Novel Small Molecule Drugs for the Treatment of Triple-Class Refractory Myeloma
September 29th 2021Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
Read More
Phase 3 Study of Coadministration of Seasonal Flu Vaccine With Prevnar 20 Shows Promising Results
September 29th 2021The researchers noted the importance of maintaining vaccination rates for conditions that can lead to respiratory issues, especially with COVID-19 cases still raising concern throughout the United States.
Read More